The global top 10 cancer drugs sales was valued at $63,619 million in 2018 and is expected to reach $129,948 million by 2026, registering a CAGR of 9.8% from 2019 to 2026. Cancer is medical condition in which abnormal cells grow with the potential to invade or spread to other parts of the body. Different forms of the drugs used for the treatment of cancer majorly include, chemotherapy, targeted therapy, immunotherapy, and others. Increase in prevalence of various forms of cancer, increase in popularity of advance therapies such as biological & targeted drug therapies, and rise in geriatric population worldwide are the key factors that drive the growth of the global cancer drugs market. Furthermore, rise in cancer awareness, increase in R&D activities, and availability of cancer drugs are expected to boost the market growth. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future. The global top 10 cancer drugs market is segmented on the basis of region into Europe (Russia, Netherlands, Switzerland, Sweden, Belgium, Austria, Norway, Denmark, Poland, Finland, Portugal, Greece, Ireland, Czech Republic, Hungary, Romania, Ukraine), Asia-Pacific (Taiwan, Indonesia, New Zealand, Singapore, Malaysia, Vietnam, Myanmar, Sri Lanka, Macau, Nepal), and LAMEA (Turkey, Venezuela, Colombia, Argentina, Iran, Israel, Chile, Algeria, UAE, Puerto Rico, Morocco, Costa Rica, Lebanon). KEY BENEFITS FOR STAKEHOLDERS - This report entails a detailed quantitative analysis along with the current global Top 10 cancer drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment. - The market size and estimations are based on a comprehensive analysis of key developments in the industry. - A qualitative analysis based on innovative products facilitates strategic business planning. - The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market Key Market Segments By Region Europe o Russia o Netherlands o Switzerland o Sweden o Belgium o Austria o Norway o Denmark o Poland o Finland o Portugal o Greece o Ireland o Czech Republic o Hungary o Romania o Ukraine LAMEA o Turkey o Venezuela o Colombia o Argentina o Iran o Israel o Chile o Algeria o United Arab Emirates o Puerto Rico o Morocco o Costa Rica o Lebanon List of key players profiled in the report: - AbbVie Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Bristol-Myers Squibb Company - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Johnson & Johnson (Janssen Global Services, LLC,) - Merck & Co., Inc. - Novartis AG - Pfizer Inc. LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request) - Sanofi S.A. - Amgen Inc. - Bayer AG